BioPharma Dive April 25, 2024
The five-and-a-half year partnership will give CRISPR drug developer Mammoth $100 million in equity and upfront cash.
Dive Brief:
- Regeneron Pharmaceuticals is upping its investment in genetic medicine, announcing Thursday a $100 million deal with CRISPR drug developer Mammoth Biosciences.
- Through their collaboration, the companies plan to develop in vivo gene therapies that combine Regeneron’s viral vector technology with Mammoth’s DNA editing platforms, which are designed to be more compact than the industry standard.
- The agreement will give Regeneron access to Mammoth’s technology for five and a half years, and provides the larger company with an option to extend the deal for another two years. The companies will jointly select research targets, while Regeneron will lead development.
Dive...
Today's Sponsors
Today's Sponsor